Health Economics›ERBB2›All lines of therapy

All lines of therapy

ERBB2 · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pertuzumab and Trastuzumab Variant #01	ERBB2	R 78 133	21d	—	—	~8	~R 326 050 indirect	—
Trastuzumab emtansine monotherapy Variant #01	ERBB2	R 41 405	21d	~7.4 mo	~29.9 mo	~2	~R 82 810 PFS proxy · indirect	7
Neratinib monotherapy Variant #02	ERBB2	R 19 339	28d	—	—	~52	~R 1 005 645 PFS proxy · indirect	1

3 of 3 regimens shown